Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
CJC-1295 No DAC Storage & Stability Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-CJCND-001
Version: 1.0
Effective Date: 10 December 2025
Product: CJC-1295 No DAC (Modified GRF 1–29) Research Peptide (RUO)
1. Product Overview
| Parameter | Specification |
|---|---|
| INN (Proposed) | CJC-1295 No DAC (Modified GRF 1–29) |
| CAS Status | 876168-09-9 (assigned) |
| Molecular Formula | C₁₅₂H₂₅₄N₄₄O₄₂ |
| Molecular Weight | 3367.95 g/mol (monoisotopic, C-terminal amidated) |
| Sequence | H-Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ala-Arg-NH₂ |
| (Key stabilising mods: DAla², Glu⁸, Leu¹⁵, Ala²⁷) | |
| Receptor Profile | Selective agonist: GHRHR (EC₅₀ ≈ 1.8 nM); no GHRP or ghrelin receptor activity |
| Form Supplied | Lyophilised Solid (white to off-white powder) |
| Purity (HPLC-UV) | ≥98% (gradient elution, C18, 220 nm) |
| Endotoxin | <1.0 EU/mg (LAL kinetic assay) |
| Residual Solvents | Meets ICH Q3C Class 3 limits |
| RUO Status | For research use only — not for human, veterinary, diagnostic, or therapeutic use |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Condition | Stability Duration | Notes |
|---|---|---|
| −20°C, desiccated, dark | ≥24 months | Preferred. D-Ala² and amidation confer high stability. Use airtight secondary container. |
| 2–8°C (refrigerated) | ≤6 months | Acceptable for active lab use; monitor for cake integrity. |
| Room Temp (≤25°C) | ≤7 days | For transit only. Avoid humidity >60% RH. |
📌 CJC-1295 No DAC is stable lyophilised, but Phe⁶ and Leu residues are hydrophobic — moisture promotes aggregation. NovaVitality uses argon headspace in all vials.
✅ Reconstituted (Solution)
| Solvent | Short-Term (2–8°C) | Long-Term (−80°C) | Notes |
|---|---|---|---|
| 0.1% acetic acid in 0.9% NaCl | ≤72 hours | ≤6 months (aliquoted) | Preferred — enhances solubility of hydrophobic core |
| Bacteriostatic water (0.9% BA) | ≤48 hours | ≤3 months (aliquoted) | Acceptable; benzyl alcohol aids solubilisation |
| PBS (pH 7.4) | ≤24 hours | Not recommended | High risk of aggregation (hydrophobic collapse) |
⚠️ Critical:
– Aliquot before freezing — limit freeze–thaw to ≤3 cycles (hydrophobic peptides aggregate irreversibly after cycle 3).
– Use low-binding tubes (e.g., LoBind Eppendorf) — hydrophobic adsorption is significant.
– Avoid repeated warming — promotes surface adhesion.
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on CJC-1295 No DAC | Detection Method |
|---|---|---|
| Moisture exposure | Hydrolysis at Asp³, Gln⁸ | HPLC peak broadening, +18 Da MS shift |
| Oxidation (Met⁰ absent; Phe⁶ present) | Phe oxidation (rare) | LC-MS: +16 Da; ↓ receptor potency |
| Aggregation | Visible haze, precipitate | DLS (>300 nm), SEC-HPLC high-MW peak |
| DPP-4 exposure | Cleavage at Tyr¹–DAla² (resistant, but not absolute) | LC-MS: −250 Da (Tyr-DAla); ↓ cAMP response |
| Repeated freeze–thaw | Irreversible oligomerisation | Loss of GHRHR potency (EC₅₀ shift >2-fold) |
🔬 Tip: Run a quick cAMP assay (HEK293-GHRHR) before critical in vivo studies — functional validation is more sensitive than purity alone.
4. Reconstitution Protocol (Best Practice)
- Equilibrate vial to room temp (15–30 min) before opening to prevent condensation.
- Centrifuge briefly (5 sec) to collect powder.
- Add solvent slowly down vial wall (e.g., 1 mL for 10 mg → 10 mg/mL stock).
- Gently swirl — do not vortex.
- If undissolved: warm to ≤37°C for 2–5 min + low-power sonication (≤30 sec, ice-cooled bath).
- Filter through 0.22 µm PVDF (low-protein-binding) for cell work.
- Aliquot into pre-chilled LoBind tubes, flash-freeze in liquid N₂, store at −80°C.
5. Analytical Verification (Post-Storage)
| Test | Acceptance Criteria | When to Run |
|---|---|---|
| HPLC Purity | ≥95% main peak | After >6 months storage, or pre-critical assay |
| LC-MS Identity | Observed MW 3368.0 ±2.0 Da | Annually, or after suspected contamination |
| Endotoxin | <5 EU/mL in reconstituted solution | Before in vivo or primary cell studies |
| Bioactivity (Required) | EC₅₀ ≤ 2.5 nM at hGHRHR (cAMP, HEK293) | For all publication or longitudinal studies |
6. References & Compliance
- Veldhuis JD et al. J Clin Endocrinol Metab. 2007;92(3):957–964. DOI: 10.1210/jc.2006-2115
- Alba M et al. Growth Horm IGF Res. 2017;35:1–8. DOI: 10.1016/j.ghir.2017.05.003
- ICH Q1A(R2): Stability Testing of New Drug Substances
- USP <1079>: Good Storage and Distribution Practices
- MHRA Guidelines on the Labelling of Unlicensed Medicines (2024) — for reference only (RUO not subject, but aligns with handling ethos)
7. Support & Documentation
📧 Technical queries: [email protected]
🔒 This datasheet is for informational purposes only. NovaVitality makes no warranties, express or implied, regarding fitness for a particular purpose. Researchers bear full responsibility for validation in their experimental context.
